
SLGC
Healthcare · Health Information Services · $396.2M market cap
Latest report
After the close
The next earnings date isn’t on the calendar yet.
Analyst consensus
Fiscal period ending Dec 31, 2023
EPS trend, 90 days to now · +11.8% over 90 days · 30-day revisions 0 up, 0 down
Beat estimates in 3 of the last 4 reported quarters.
EPS surprise versus the estimate at the time of the report.
| Date | Session | Estimate | Actual | Surprise |
|---|---|---|---|---|
| Nov 8, 2023 | After the close | -0.17 | -0.12 | +29.4% |
| Aug 14, 2023 | After the close | -0.15 | -0.13 | +13.3% |
| May 11, 2023 | After the close | -0.22 | -0.18 | +18.2% |
| Mar 28, 2023 | After the close | -0.21 | -0.26 | -23.8% |
| Nov 14, 2022 | Before the open | -0.20 | -0.18 | +10.0% |
| Aug 15, 2022 | After the close | -0.18 | -0.13 | +27.8% |
| May 12, 2022 | After the close | -0.16 | -0.02 | +87.5% |
| Mar 29, 2022 | After the close | -0.13 | -0.13 | 0.0% |
| Oct 15, 2021 | After the close | -0.55 | -0.11 | +80.0% |
| Aug 12, 2021 | Time not confirmed | — | -0.10 | — |
| May 24, 2021 | Time not confirmed | — | -0.78 | — |
SomaLogic, Inc. operates as a protein biomarker discovery and clinical diagnostics company in the United States. It develops slow off-rate modified aptamers (SOMAmers), which are modified nucleic acid-based protein binding reagents that are specific for its cognate protein; and offers proprietary SomaScan services, which provide multiplex protein detection and quantification of protein levels in complex biological…